Skip to content
10-Q

Quarterly Report

Coeptis Therapeutics, Inc.

0001683168-21-005683

← back to feed
Filed
Nov 15, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2021 · Nov 15, 2021 36.44M sh
Capex Q3 2021 · Sep 30, 2021 $0
Capex Q3 2021 · Sep 30, 2020 $0
Long Term Debt Q3 2021 · Sep 30, 2021 $1.65M
Long Term Debt Q3 2021 · Dec 31, 2020 $150K
Current Liabilities Q3 2021 · Sep 30, 2021 $5.45M
Current Liabilities Q3 2021 · Dec 31, 2020 $5.28M
Total Liabilities Q3 2021 · Sep 30, 2021 $7.11M
Total Liabilities Q3 2021 · Dec 31, 2020 $5.44M
Current Assets Q3 2021 · Sep 30, 2021 $2.84M
Current Assets Q3 2021 · Dec 31, 2020 $224.75K
Total Assets Q3 2021 · Sep 30, 2021 $7.68M
Total Assets Q3 2021 · Dec 31, 2020 $300.48K
Operating Cash Flow Q3 2021 · Sep 30, 2020 −$2.55M
Stockholders Equity Q3 2021 · Sep 30, 2020 −$2.99M
Stockholders Equity Q3 2021 · Jun 30, 2020 −$1.92M
Stockholders Equity Q3 2021 · Mar 31, 2020 −$1.57M
Stockholders Equity Q3 2021 · Dec 31, 2019 $621.53K
Sga Expense Q3 2021 · Sep 30, 2020 $1.43M
Sga Expense Q3 2021 · Sep 30, 2020 $2.44M
Rd Expense Q3 2021 · Sep 30, 2020 $0
Rd Expense Q3 2021 · Sep 30, 2020 $3.54K
Net Income Q3 2021 · Sep 30, 2020 −$1.82M
Net Income Q3 2021 · Sep 30, 2020 −$4.39M
Operating Income Q3 2021 · Sep 30, 2020 −$1.61M
Operating Income Q3 2021 · Sep 30, 2020 −$2.68M
Gross Profit Q3 2021 · Sep 30, 2020 $8.4K
Gross Profit Q3 2021 · Sep 30, 2020 $27.4K
Cost Of Revenue Q3 2021 · Sep 30, 2020 $1.49K
Cost Of Revenue Q3 2021 · Sep 30, 2020 $3.36K
Revenue Q3 2021 · Sep 30, 2020 $9.89K
Revenue Q3 2021 · Sep 30, 2020 $30.76K